Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!

Active, Not Recruiting

An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. - CA009-002

Updated: 16 April, 2018   |   ClinicalTrials.gov

Print Friendly Summary

Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1/Phase 2


  • Gender(s)

  • 18+

    Age Range

  • Active, Not Recruiting

Treatment Options

Study Arms
Experimental: Combination therapy - BMS-986156 + Nivolumab (Dose Escalation)
Drug: Nivolumab Drug: BMS-986156
Experimental: Combination therapy - BMS-986156 + Nivolumab (Dose Expansion)
Drug: Nivolumab Drug: BMS-986156
Experimental: Mono therapy - BMS-986156 (Dose Escalation)
Drug: BMS-986156
Experimental: Mono therapy - BMS-986156 (Dose Expansion)
Drug: BMS-986156

Key Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - For Dose Escalation: - Subjects with any previously treated advanced (metastatic or refractory) solid tumor - For Cohort Expansion: - Subjects must have a previously treated advanced solid tumor to be eligible - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Willing and able to provide pre-treatment and on-treatment fresh tumor biopsy - Women of child-bearing potential and men must use an acceptable method of contraception during treatment and for 23 weeks after treatment for women and 31 weeks for men Exclusion Criteria: - Known central nervous system metastases or central nervous system as the only source of disease - Other concomitant malignancies (with some exceptions per protocol) - Active, known or suspected autoimmune disease - Uncontrolled or significant cardiovascular disease - History of active or chronic hepatitis (e.g. Hep B or C) - Impaired liver or bone marrow function - Major surgery less than 1 month before start of the study

Have questions? Email Us

Have questions?
Email Us